It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Pharmaceutical
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (ON 123300) is being evaluated in a Phase II trial. Onconova listed on NASDAQ in 2013.
CEO
Steven M. Fruchtman
Therapeutics
Pennsylvania, USA
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
